Image 4_Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.tif

Introduction<p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for advanced cancers, yet their efficacy remains heterogeneous among patients. Tumor mutation burden (TMB) has been extensively explored as a potential biomarker for predicting ICI response. However,...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Wuyuan Liao (21776432) (author)
مؤلفون آخرون:	Xinwei Zhou (6176357) (author), Hansen Lin (805525) (author), Zihao Feng (3538655) (author), Xinyan Chen (758454) (author), Yuhang Chen (584479) (author), Minyu Chen (14821353) (author), Mingjie Lin (11957492) (author), Gaosheng Yao (15859679) (author), Jinwei Chen (784194) (author), Haoqian Feng (21776450) (author), Yinghan Wang (2062750) (author), Zhiping Tan (233498) (author), Youyan Tan (21776453) (author), Jun Lu (36049) (author), Pengju Li (2553166) (author), Jinhuan Wei (301339) (author), Li Luo (149019) (author), Liangmin Fu (13885353) (author)
منشور في:	2025
الموضوعات:	Genetic Immunology immune checkpoint inhibitor tumor mutation burden tumor microenvironment pan-cancer biomarker
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Image 4_Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.tif

مواد مشابهة